Mentioned in ?
References in periodicals archive ?
The ACIP recommendation calls for pneumococcal vaccine-naive adults aged 65 and older to receive one dose of 13-valent pneumococcal conjugate vaccine (PCV13), followed by a dose of 23-valent pneumococcal polysaccharide vaccine (PPSV23) 6-12 months later (MMWR 2014:63;822-5).
In this study, HIV-infected individuals aged 18 years and older who had been previously vaccinated with at least one dose of the conventional pneumococcal polysaccharide vaccine (PPSV) received three doses of Prevnar 13 given six months apart.
Similarly, the pneumococcal polysaccharide vaccine (PPSV) is another preventive measure that is easily implemented in the long-term care facility.
The report covers the Americas, and the EMEA and APAC regions; it also covers the Pneumococcal Polysaccharide Vaccines and Pneumococcal Conjugate Vaccines market landscape and its growth prospects in the coming years.
The currently available pneumococcal polysaccharide vaccine, is manufactured by both Merck (Pneumovax 23) and Lederie Laboratories (Pnu-Immune 23), and includes 23 purified capsular polysaccharide antigens (serotypes 1 ,2,3,4,5,6B,7F,8,9N,9V,10A,11A,12F,14 , 15B,17F,18C,19A,19F,20,22F,23F and 33F).
A single dose is required every year for seasonal influenza while a single dose of the pneumococcal polysaccharide vaccine is needed every five years.
About PCV and PPV: PPV: Pneumococcal polysaccharide vaccine (PPV), is a vaccine used to prevent Streptococcus pneumoniae (pneumococcus) infections such as pneumonia and septicaemia.
First and second dose antibody responses to pneumococcal polysaccharide vaccine in infants.
Washington, Jan 6 (ANI): Researchers from Switzerland and the UK have found that commonly used pneumococcal polysaccharide vaccines (PPVs) do not seem to be effective for preventing pneumonia.
Through its part B, Medicare covers the pneumococcal polysaccharide vaccine, the influenza vaccine, and (for high-risk adults) the hepatitis B vaccine, and it covers most other adult vaccinations through part D, including the shingles vaccine.
Pneumolysin represents a particularly attractive antigen on which to base the development of a protein vaccine for the following reasons: (i) it is produced by almost all clinically relevant strains of the pneumococcus; (ii) it induces T-lymphocyte-dependent immune responses resulting in protective, antibody-mediated systemic and mucosal immunity as alluded to above; and (iii) inactivated pneumolysin (toxoid) has been demonstrated to function not only as a protective immunogen per se, but also as an effective immunogenic carrier of pneumococcal polysaccharide in murine models of conjugate vaccine efficacy, being equivalent or superior to conventional carriers such as tetanus toxoid.
Several investigators have evaluated the immune response to individual pneumococcal polysaccharide serotypes (13-21), but some issues remain unsolved.

Full browser ?